RITTER PHARMACEUTICALS INC (62)

Browse by Contract Category

Contracts

Letter dated June 22, 2021 to A.G.P./Alliance Global Partners giving notice of termination of Sales Agreement (Filed With SEC on August 16, 2021)
Hire offer letter from the Company to Tariq Arshad, dated April 22, 2021 (Filed With SEC on August 16, 2021)
Two-Year Common Stock Purchase Warrant for 1,348,314 shares, dated December 18, 2020 (Filed With SEC on December 18, 2020)
Exclusive License Agreement, by and between the Company and University of Louisville Research Foundation, Inc. dated as of June 9, 2020 (Filed With SEC on August 14, 2020)
Standard template of Stock Option Agreement for use under 2020 Stock Incentive Plan (Filed With SEC on June 11, 2020)
Agreement and Plan of Merger, dated January 15, 2020, by and among Ritter Pharmaceuticals, Inc., RPG28 Merger Sub, Inc. and Qualigen, Inc (Filed With SEC on January 21, 2020)
Amendment to Distribution and Development Agreement between Sekisui Diagnostics, LLC and Qualigen, Inc., dated as of July 1, 2021 [signed August 2, 2021] (Filed With SEC on August 13, 2021)
Novation Agreement among the Company, Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated March 1, 2021 (Filed With SEC on May 14, 2021)
Novation Agreement among the Company, Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated January 30, 2021 (Filed With SEC on May 14, 2021)
Placement Agency Agreement between Qualigen Therapeutics, Inc. and A.G.P./Alliance Global Partners, dated December 15, 2020 (Filed With SEC on December 18, 2020)
Securities Purchase Agreement, dated December 16, 2020 (Filed With SEC on December 18, 2020)
Deferred Common Stock Purchase Warrant for 842,696 shares, dated December 18, 2020 (Filed With SEC on December 18, 2020)
Prefunded Common Stock Purchase Warrant for 1,000,000 shares, dated December 18, 2020 (Filed With SEC on December 18, 2020)
Technology Transfer Agreement dated as of October 7, 2020 between Qualigen, Inc. and Yi Xin Zhen Duan Jishu (Suzhou) Ltd (Filed With SEC on October 9, 2020)
Letter agreement (for payment date extension) between the Company and Sekisui Diagnostics, LLC dated June 23, 2020 (Filed With SEC on August 14, 2020)
Letter agreement amending M&A Advisory Agreement between the Company and A.G.P./Alliance Global Partners dated May 20, 2020 (Filed With SEC on August 14, 2020)
Exclusive License Agreement, by and between Qualigen Therapeutics, Inc. and University of Louisville Research Foundation, Inc. dated as of July 17, 2020 (Filed With SEC on August 4, 2020)
Common Stock Purchase Warrant for 1,287,829 shares, dated August 4, 2020 (Filed With SEC on August 4, 2020)
Placement Agency Agreement between Qualigen Therapeutics, Inc. and A.G.P./Alliance Global Partners, dated August 2, 2020 (Filed With SEC on August 4, 2020)
Securities Purchase Agreement, dated August 2, 2020 (Filed With SEC on August 4, 2020)
Pre-Funded Common Stock Purchase Warrant for 1,920,768 shares, dated July 10, 2020 (Filed With SEC on July 10, 2020)
Securities Purchase Agreement, dated July 8, 2020 - corrected (Filed With SEC on July 10, 2020)
Common Stock Purchase Warrant for 1,920,768 shares, dated July 10, 2020 (Filed With SEC on July 10, 2020)
Placement Agency Agreement between the Company and A.G.P./Alliance Global Partners, dated July 8, 2020 (Filed With SEC on July 9, 2020)
Form of Pre-Funded Warrant expected to be issued July 10, 2020 (Filed With SEC on July 9, 2020)
Form of Warrant expected to be issued July 10, 2020 (Filed With SEC on July 9, 2020)
Securities Purchase Agreement between the Company and certain Purchasers, dated July 8, 2020 (Filed With SEC on July 9, 2020)
Warrant, issued by the Company in favor of Alpha Capital Anstalt, dated May 22, 2020 [post-Merger] (Filed With SEC on May 29, 2020)
Form of Lock-Up Agreement (Filed With SEC on May 29, 2020)
Form of Indemnification Agreement - Qualigen, Inc (Filed With SEC on May 29, 2020)
2020 Stock Equity Incentive Plan (Filed With SEC on May 29, 2020)
Consulting Agreement, by and between the Company and CFB Financial, Inc., dated as of May 22, 2020 (Filed With SEC on May 29, 2020)
Consulting Agreement, by and between the Company and Stonehenge Partners, LLC, dated as of May 22, 2020 (Filed With SEC on May 29, 2020)
Consulting Agreement, by and between the Company and Andrew J. Ritter, dated as of May 22, 2020 (Filed With SEC on May 29, 2020)
Notice of Grant of Stock Option / Stock Option Agreement, by and between the Company and John Beck, dated as of May 18, 2020 (Filed With SEC on May 29, 2020)
Notice of Grant of Stock Option / Stock Option Agreement, by and between the Company and Ira E. Ritter, dated as of May 18, 2020 (Filed With SEC on May 29, 2020)
Notice of Grant of Stock Option / Stock Option Agreement, by and between the Company and Andrew J. Ritter, dated as of May 18, 2020 (Filed With SEC on May 29, 2020)
Amendment to Consulting Agreement, by and between Qualigen, Inc. and GreenBlock Capital LLC, dated as of March 6, 2020 (Filed With SEC on May 29, 2020)
Warrant, issued by Qualigen, Inc. in favor Alpha Capital Anstalt, dated May 22, 2020 [pre-Merger] (Filed With SEC on May 29, 2020)
Securities Purchase Agreement, by and between Qualigen, Inc. and Alpha Capital Anstalt, dated May 20, 2020 (Filed With SEC on May 29, 2020)
Form of Warrant, issued by the Company in favor of GreenBlock Capital LLC and its designees, dated May 22, 2020 [post-Merger] (Filed With SEC on May 29, 2020)
Form of Warrant, issued by Qualigen, Inc. in favor of GreenBlock Capital LLC and its designees, dated May 22, 2020 [pre-Merger] (Filed With SEC on May 29, 2020)
Amendment No. 2 to Consulting Agreement, by and between Qualigen, Inc. and GreenBlock Capital LLC, dated as of May 3, 2020 (Filed With SEC on May 29, 2020)
Consulting Agreement, by and between Qualigen, Inc. and GreenBlock Capital LLC, dated as of August 22, 2018 (Filed With SEC on May 29, 2020)
Executive Employment Agreement, by and between Qualigen, Inc. and Shishir Sinha, dated as of February 1, 2017 and as amended on January 9, 2018 (Filed With SEC on May 29, 2020)
Executive Employment Agreement, by and between Qualigen, Inc. and Christopher Lotz, dated as of February 1, 2017 and as amended on January 9, 2018 (Filed With SEC on May 29, 2020)
Executive Employment Agreement, by and between Qualigen, Inc. and Michael Poirier, dated as of February 1, 2017 and as amended on January 9, 2018 (Filed With SEC on May 29, 2020)
Contingent Value Rights Agreement, dated May 22, 2020, by and among the Company, John Beck in the capacity of CVR Holders Representative and Andrew J. Ritter in his capacity as a... (Filed With SEC on May 29, 2020)
Description of Common Stock (Filed With SEC on March 31, 2020)
Form of Agreement to Exchange Warrants (Filed With SEC on February 21, 2020)
Form of CVR Agreement, by and among Ritter Pharmaceuticals, Inc., Andrew Ritter, in his capacity as the initial CVR Holders Representative, and Andrew Ritter, in his capacity as a... (Filed With SEC on January 21, 2020)
Form of Consent and Waiver with Series B Convertible Preferred Stockholders (Filed With SEC on November 14, 2019)
Sales Agreement dated November 6, 2019 between the Registrant and A.G.P./Alliance Global Partners (Filed With SEC on November 7, 2019)
Offer Letter Amendment by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter dated October 15, 2019 (Filed With SEC on October 15, 2019)
Offer Letter Amendment by and between Ritter Pharmaceuticals, Inc. and John W. Beck, dated October 15, 2019 (Filed With SEC on October 15, 2019)
Offer Letter Amendment by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter, dated October 15, 2019 (Filed With SEC on October 15, 2019)
Amended and Restated Common Stock Purchase Agreement, by and between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund, LLC, dated July 23, 2019 (Filed With SEC on July 24, 2019)
Amended and Restated Registration Rights Agreement, dated July 23, 2019, by and between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (Filed With SEC on July 24, 2019)
Amended and Restated Common Stock Purchase Agreement, dated July 23, 2019, between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (Filed With SEC on July 24, 2019)
Amended and Restated Registration Rights Agreement, dated July 23, 2019, between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (Filed With SEC on July 24, 2019)
Amended and Restated Common Stock Purchase Agreement, by and between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund, LLC, dated March 29, 2019 (Filed With SEC on April 1, 2019)
Form of Performance Restricted Stock Unit Award Agreement (Filed With SEC on April 1, 2019)